8-K filed Aug 5, 2026 at 06:02 ET
BeOne Medicines reported Q2 2026 revenue of $1.71B (+30% YoY) and GAAP diluted EPS of $2.05/ADS, with raised FY2026 revenue guidance to $6.6B-$6.8B and GAAP operating income guidance to $1.0B-$1.1B. The quarter was driven by BRUKINSA global sales of $1.2B (+31% YoY) and FDA accelerated approval for BEQALZI (sonrotoclax) in RR MCL. The raised guidance and strong operational leverage signal accelerating profitability, making this a clear positive catalyst for the stock.